Currently Funded projects


GRIFFITH UNIVERSITY, Institute for Glycomics

close the gaps in sarcoma diagnoses and treatment to deliver novel diagnostic technologies and precision treatment options to improve patient outcomes.


We are delighted to announce a major new partnership with Griffith University’s Institute for Glycomics, a translational biomedical research Institute based on the Gold Coast with a focus on developing vaccines, diagnostics and personalised treatments for a wide range of cancers, infectious diseases and neurological disorders.

Read more >




WEHI (Walter and Eliza Hall Institute)

An innovative approach to tackling treatment resistance in medulloblastoma by using bioinformatics and machine learning 


Medulloblastoma is a devastating brain cancer with few treatment options that largely affects children and young adults. It is the most common childhood brain cancer. Sadly, for patients that relapse following treatment, there are no effective therapies and relapse is lethal.

Read more >



Hudson Monash Paediatric Precision Medicine (HMPPM) Program

Dilru Habarakad, is the Australian Lions Childhood Cancer Research Foundation (ALCCRF) Biobank Specialist for the Hudson Monash Paediatric Precision Medicine (HMPPM) Program.

Read more >






Telethon Kids Institute Paediatric Cancer Immunotherapy

Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to the Telethon Kids Institute.

The funding will support the Telethon Kids Cancer Centre’s vital research aimed at improving survival rates, longevity and quality of life for children with cancer.

(at left) ALCCRF Trustee, Peter Lamb, with Telethon Kids cancer researcher and clinician, Dr Rishi Kotecha.


Read more >


“Cage Fighting” Neuroblastoma

Dr Andrew Care: Macquarie University

Engineering a protein nanocage for targeted ionophoric-copper therapy

Read more >



Novel targets for paediatric brain tumour immunotherapy

Dr Pouya Faridi: Monash University

Every year more than 170 Australian children are diagnosed with brain cancer. Diffuse Intrinsic Pontine Glioma (DIPG) is the most aggressive childhood brainstem tumour with no cure and median survival   of   only  nine  months post – diagnosis. Cancer vaccination is an emerging approach for untreatable cancers.

Read More



Exploiting and enhancing brain-resident immune cells for the treatment of paediatric brain stem glioma (DIPG) 

Dr Jessica Buck:  University of Western Australia / Telethon Kids Institute

DIPG is a fatal brain cancer that affects children, with no effective treatments. This research project is proposing a new combination of treatments targeting the immune system in the brain to treat DIPG. First, the cancer cells will be labelled with a “flag” so the immune system can see them.

Read More